Lindsey Roeker, MD Memorial Sloan-Kettering Cancer Center 5Live #ASCO20
3:55
Key Insights on Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
Key Insights on Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
Chronic Lymphocytic Leukemia Similar Videos
-
Practical issues in CLL care: oral adherence, MRD testing, and managing treatment-related adverse events_Nicole Lamanna, MD; #BeyondASCO
12:51
-
Module 5: Experts Debate Optimal Selection and Sequencing Strategies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE
21:45
-
Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE
9:28